Targeted therapy treats advanced ovarian cancer

A Phase 3 clinical study, sponsored by the National Cancer Institute and conducted by the Gynecologic Oncology Group, demonstrated that the targeted therapy bevacizumab effectively delayed advanced ovarian cancer progression. The research found that this treatment may serve as a supplement to the typical surgery and chemotherapy treatment. The study used 1,873 patients with stage III ovarian cancer that could not be absolutely removed with surgery, or stage IV ovarian cancer. The overarching result was a 28 percent reduction in the risk disease of ovarian cancer progression. The New England Journal of Medicine published the trial results in their December 29 issue.


SOURCE: Fox Chase Cancer Center